With no treatment options currently available for geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), pegcetacoplan could fill a huge unmet need, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
With no treatment options currently available for geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), pegcetacoplan could fill a huge unmet need, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
The drug is currently under review for approval with the FDA, which is expected to make a decision by February 26.
Transcript
There will be multiple presentations on the 2-year outcomes of the DERBY and OAKS trials of pegcetacoplan. What is the importance of this drug for the field?
It's such an exciting time for geographic atrophy. As we all know, geographic atrophy is a huge unmet need, and a drug approval during AMD Awareness Month would be a game changer for very large aging population. GA is a leading cause of blindness worldwide. Again, a huge clinical unmet need. If this happens, and we start developing treatments for this disease, this would constitute the most important advance in ophthalmology in the past decade.
GA affects 1 million individuals in the United States and 5 million worldwide, so a large population will be impacted. It's truly so important to begin to have a treatment for this disease in our clinics to offer our patients.
Based on the number of cases, why is there a disproportionate number of cases in the United States? Is geographic atrophy underrecognized or underdiagnosed globally?
Most likely. Because we haven't had any available treatments to date, I firmly believe that a lot of the dry AMD patients from earlier stages, but also geographic atrophy, are hiding in the comprehensive optometric clinics. There's no reason to refer them for retinal assessments or diagnosis and staging of the disease, because we've had absolutely no approved options for this disease.
As you know, the only interventions we can offer are the AREDS vitamins to slow the progression to the wet form or low-vision therapy for the really impacted patients. But truly no treatments have been approved for an option so far, so, why refer?
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More